Patents Issued in December 20, 2018
-
Publication number: 20180362549Abstract: The invention relates to complexing agents of formula (I) in which A1, A2, A3 and R1 are as defined in the description. The invention also relates to lanthanide complexes obtained from said complexing agents. The invention can be used for marking biological molecules.Type: ApplicationFiled: December 9, 2016Publication date: December 20, 2018Inventors: Laurent LAMARQUE, Claude PICARD, Chantal GALAUP, Nadine LEYGUE, Jurriaan ZWIER, Emmanuel BOURRIER
-
Publication number: 20180362550Abstract: The invention relates to cationic complexes made up of a lanthanide ion Ln3+ and a ligand of formula (I) : with X, Y and R1 as defined in claim 1, and to the salts thereof with an anion, the solvates and hydrates thereof; with the exception of cationic complexes made up of a lanthanide ion Ln3+ and a ligand of one of formulae (I.1) or (I.4) as defined in claim 1, and the salts, solvates and hydrates thereof. The invention also relates to the use of such a complex or of a cationic complex made up of a lanthanide ion Ln3+ and a ligand of formula (I.1) or (I.4) as defined in claim 1, or of one of the salts thereof with an anion, the solvates or hydrates thereof, as an aid to the crystallisation of a biological macromolecule, as well as to crystallisation methods and methods for analysing or determining the structure of a biological macromolecule.Type: ApplicationFiled: December 16, 2016Publication date: December 20, 2018Applicants: ECOLE NORMALE SUPERIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON I, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Oliver MAURY, Eric GIRARD, Sylvain ENGILBERGE, François RIOBE
-
Publication number: 20180362551Abstract: The present disclosure relates to a process for forming a refined metal-containing unit by reducing yield impurities with acidified deionized water. Another embodiment is a composition comprising the refined metal-containing unit. Yet another embodiment is a process for forming a patterned substrate by depositing a composition comprising the refined metal-containing unit on a substrate, drying the film comprising the refined metal-containing unit, exposing the film comprising the refined metal-containing composition to a source of actinic radiation, and transferring the pattern to substrate. The disclosed embodiments are useful in producing patterned substrates by direct or indirect pattern transfer from films comprising the refined metal-containing unit.Type: ApplicationFiled: September 29, 2015Publication date: December 20, 2018Applicant: Pryog, LLCInventors: Stephanie Dilocker, Joseph J Schwab
-
Publication number: 20180362552Abstract: There is provided a betaine-based silicon compound which exhibits the effect of hydrophilizating and defogging a surface. The betaine-based silicon compound is represented by formula (1). X13-m(CH3)mSi—R1—(Y1—R2)n}o—N+(R3)p(R4)q—Y2COO?(1) {In the formula: X1 represents an alkoxy group with 1 to 5 carbon atoms or a halogen atom which may be identical to or different from one another; m represents 0 or 1; R1 represents an alkylene group with 1 to 5 carbon atoms; Y1 represents —NHCOO—, —NHCONH—, —S—, or —SO2—; n represents 0 or 1; R2 represents an alkylene group with 1 to 10 carbon atoms or —CH2CH2N+(CH3)(Y2COO?)CH2CH2OCH2CH2—; o represents 1, 2 or 3; R3 and R4 represent an alkyl group with 1 to 5 carbon atoms which may be identical to or different from one another; Y2 represents —CH2— or the like; p and q represent 0 or 1; provided that o+p+q equals 3.Type: ApplicationFiled: March 25, 2016Publication date: December 20, 2018Applicant: KRI, Inc.Inventors: Masahiro Satoh, Satsuki Kitajima
-
Publication number: 20180362553Abstract: Compounds having hindered amine and oxyalkyl amine light stabilizers can mitigate the adverse effects of actinic radiation, such as visible and ultraviolet light, in particular on substrates such as glass or ceramic substrates. Polymers derived from such compounds. Nanoparticles, substrates, such as glass or ceramic substrates, or both nanoparticles and substrates, having such compounds affixed thereto. Articles containing at least one of such polymers, nanoparticles, substrates, or compounds.Type: ApplicationFiled: August 28, 2018Publication date: December 20, 2018Inventors: Thomas P. Klun, Mark A. Roehrig, Joseph C. Spagnola, Alan K. Nachtigal, Charles J. Hoy, Richard J. Pokorny, William J. Hunt, Jason T. Petrin, Paul B. Armstrong, Suresh S. Iyer
-
Publication number: 20180362554Abstract: The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.Type: ApplicationFiled: December 12, 2016Publication date: December 20, 2018Applicant: ETH ZurichInventors: Mattias IVARSSON, Jean-Christophe LEROUX, Bastien CASTAGNER
-
Publication number: 20180362555Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.Type: ApplicationFiled: August 24, 2018Publication date: December 20, 2018Applicants: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS, KING SAUD UNIVERSITYInventors: Said S. AL-JAROUDI, Ali ALHOSHANI, Muhammad ALTAF, Anvarhusein Abdulkadir ISAB
-
Publication number: 20180362556Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.Type: ApplicationFiled: August 24, 2018Publication date: December 20, 2018Applicants: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS, KING SAUD UNIVERSITYInventors: Said S. AL-JAROUDI, Ali ALHOSHANI, Muhammad ALTAF, Anvarhusein Abdulkadir ISAB
-
Publication number: 20180362557Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.Type: ApplicationFiled: August 24, 2018Publication date: December 20, 2018Applicants: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS, KING SAUD UNIVERSITYInventors: Said S. Al-Jaroudi, Ali Alhoshani, Muhammad Altaf, Anvarhusein Abdulkadir Isab
-
Publication number: 20180362558Abstract: An aqueous curable composition includes a water-soluble photopolymerization initiator having a structure in which one or more carbonyl groups further directly bond to an aromatic ring of an aromatic acyl group that bonds to a phosphorus atom in an acylphosphine oxide structure, water, and a polymerizable compound. A novel water-soluble photopolymerization initiator is a compound represented by formula 1-1 or formula 2-1.Type: ApplicationFiled: August 22, 2018Publication date: December 20, 2018Inventors: Kazuhiro YOKOI, Hiroaki TSUYAMA
-
Publication number: 20180362559Abstract: A compound of Formula I has the structure: wherein G is a straight, branched or cyclic alkyl group having 2 to 50 carbon atoms or an ether group, and R is a fluorescent dye. In some embodiments, G is selected from the group consisting of —(CH2)n— and —(CH2OCH2)m—, wherein n is an integer from 2 to 18, m is an integer from 2 to 18.Type: ApplicationFiled: September 21, 2016Publication date: December 20, 2018Applicant: University of Southern CaliforniaInventors: Charles E. MCKENNA, Boris A. KASHEMIROV, Kim NGUYEN
-
Publication number: 20180362560Abstract: The present invention provides novel phospholipidated imidazoquinolines of formula (I) as TLR7 and TLR8 agonists, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: ApplicationFiled: December 12, 2016Publication date: December 20, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Helene G. BAZIN-LEE, David A. JOHNSON
-
Publication number: 20180362561Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.Type: ApplicationFiled: September 15, 2016Publication date: December 20, 2018Applicant: The Regents of the University of CaliforniaInventors: Karl Y. HOSTETLER, James R. BEADLE, Nadejda VALIAEVA
-
Publication number: 20180362562Abstract: Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 5, 2016Publication date: December 20, 2018Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Izzat Tiedje Raheem, Timothy J. Hartingh, John Schreier, Jean-Laurent Paparin
-
Publication number: 20180362563Abstract: Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 12, 2016Publication date: December 20, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Wenlang Fu, Zhiqiang Guo, Ning Qi, Izzat T. Raheem, Petr Vachal, Ming Wang, John D. Schreier
-
Publication number: 20180362564Abstract: Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.Type: ApplicationFiled: December 8, 2016Publication date: December 20, 2018Inventors: Maria Beconi, Daniel Elbaum, Steven Harper, Savina Malancona
-
Publication number: 20180362565Abstract: The present invention provides a method for producing a cyclometalated iridium complex by use of a non-chlorine iridium raw material. The method for producing a cyclometalated iridium complex includes producing a cyclometalated iridium complex by reacting a raw material including an iridium compound with an aromatic heterocyclic bidentate ligand capable of forming an iridium-carbon bond, the raw material being non-halogenated iridium having a conjugated base of a strong acid as a ligand. Here, the non-halogenated iridium is preferably one containing a conjugated base of a strong acid having a pKa of 3 or less as a ligand.Type: ApplicationFiled: December 22, 2016Publication date: December 20, 2018Inventors: Hideo KONNO, Junichi TANIUCHI, Ryosuke HARADA, Toshiyuki SHIGETOMI, Rumi KOBAYASHI, Yasushi MASAHIRO
-
Publication number: 20180362566Abstract: Metal complexes such as those of formula (I) are contemplated by the present invention. The metal complexes may be used in catalytic reactions as a catalyst. The catalytic reaction may be an autotransfer process, for example hydrogen borrowing.Type: ApplicationFiled: December 19, 2016Publication date: December 20, 2018Inventors: Stephen Philip MARSDEN, Patrick Columba MCGOWAN, Roberta LANARO, Andrew John BLACKER
-
Publication number: 20180362567Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.Type: ApplicationFiled: June 14, 2018Publication date: December 20, 2018Inventors: Kyuyoung HWANG, Sangdong KIM, Sungjun KIM, Soyeon KIM, Jungin LEE, Jiyoun LEE, Yoonhyun KWAK, Ohyun KWON
-
Publication number: 20180362568Abstract: Provided is a cobalt complex which is useful for the production of a cobalt-containing thin film under conditions where no oxidizing gas is used. A cobalt complex represented by general formula (1) (wherein R1 represents a silyloxy group represented by general formula (2) (wherein R6, R7 and R8 independently represent an alkyl group having 1 to 6 carbon atoms); R2 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a silyloxy group represented by general formula (2); R3, R4 and R5 independently represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and L represents a diene having 4 to 10 carbon atoms) is used.Type: ApplicationFiled: December 12, 2016Publication date: December 20, 2018Inventors: Naoyuki KOISO, Yuki YAMAMOTO, Hiroyuki OIKE, Teppei HAYAKAWA, Taishi FURUKAWA, Ken-ichi TADA
-
Publication number: 20180362569Abstract: The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements.Type: ApplicationFiled: December 16, 2016Publication date: December 20, 2018Inventors: Martin MATWIEJUK, Pierre CHASSAGNE, Markus HEDEROS
-
Publication number: 20180362570Abstract: The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD+ levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.Type: ApplicationFiled: June 19, 2018Publication date: December 20, 2018Inventors: Gangadhara GANAPATI, Atignal Shankara Rao ARVIND
-
Publication number: 20180362571Abstract: Disclosed is a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. Also disclosed is a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate.Type: ApplicationFiled: December 9, 2016Publication date: December 20, 2018Inventors: Mani B. Kotala, Venkata L. Dammalapati
-
Publication number: 20180362572Abstract: Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.Type: ApplicationFiled: August 30, 2018Publication date: December 20, 2018Applicant: AM CHEMICALS LLCInventors: Andrei Pavel GUZAEV, Vladimir Y. VVEDENSKIY
-
Publication number: 20180362573Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v): and wherein L1, L2, L3, X1, X2, Y, RZ4, RZ5, RZ6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.Type: ApplicationFiled: August 28, 2018Publication date: December 20, 2018Inventors: Ravindra B. Upasani, Boyd L. Harrison, Benny C. Askew, Jean-Cosme Dodart, Francesco G. Salituro, Albert Jean Robichaud
-
Publication number: 20180362574Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.Type: ApplicationFiled: April 13, 2018Publication date: December 20, 2018Applicants: Massachusetts Institute of Technology, Yale UniversityInventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
-
Publication number: 20180362575Abstract: Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.Type: ApplicationFiled: October 21, 2016Publication date: December 20, 2018Inventors: Ralph Mazitschek, Yanbing Ding, Kaisheng Shen
-
Publication number: 20180362576Abstract: The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.Type: ApplicationFiled: July 27, 2018Publication date: December 20, 2018Applicant: BIOATLA, LLCInventor: Jay M. Short
-
Publication number: 20180362577Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.Type: ApplicationFiled: May 10, 2018Publication date: December 20, 2018Inventors: Per-Göran Gillberg, Hans Graffner, Ingemar Starke
-
Publication number: 20180362578Abstract: The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.Type: ApplicationFiled: June 12, 2018Publication date: December 20, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Julien Beignet, Konrad Bleicher, Bernhard Fasching, Hans Hilpert, Taishan Hu, Dwight MacDonald, Stephen Jackson, Sabine Kolczewski, Carsten Kroll, Adrian Schaeublin, Hong Shen, Theodor Stoll, Helmut Thomas, Amal Wahhab, Claudia Zampaloni
-
Publication number: 20180362579Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: ApplicationFiled: January 9, 2018Publication date: December 20, 2018Inventors: D. Travis WILSON, Marc W. ANDERSEN, Elizabeth MEAD
-
Publication number: 20180362580Abstract: The present disclosure provides crystalline carfilzomib form M1 and a process for the preparation thereof. Further disclosed are processes for the preparation of amorphous carfilzomib using crystalline form M1 as a starting material. The present disclosure also relates to an improved process for the preparation of carfilzomib.Type: ApplicationFiled: December 10, 2016Publication date: December 20, 2018Applicant: Mylan Laboratories LimitedInventors: Vinayak Gore, Vinay Kumar Shukla, Yogesh Sangvikar, Dattatrey Kokane, Sushant Gharat
-
Publication number: 20180362581Abstract: The present invention provides MPHOSPH1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.Type: ApplicationFiled: October 6, 2016Publication date: December 20, 2018Applicant: OncoTherapy Science, Inc.Inventors: Sachiko YAMASHITA, Tetsuro HIKICHI
-
Publication number: 20180362582Abstract: The present invention provides a macrocyclic compound of formula (I) compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.Type: ApplicationFiled: June 18, 2018Publication date: December 20, 2018Inventors: Éric Marsault, Marc Sousbie, Richard Leduc, Philippe Sarret, Jean-Michel Longpré, Élie Besserer-Offroy, Rebecca Brouillette, Michael Desgagné
-
Publication number: 20180362583Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: ApplicationFiled: August 27, 2018Publication date: December 20, 2018Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
-
Publication number: 20180362584Abstract: This disclosure relates to peptides useful for targeting inflamed or distressed tissue and uses related thereto. In certain embodiment, the peptides comprise SEQ ID NO: 1-14, or variants or derivatives thereof. In certain embodiments, peptides disclosed herein are conjugated to a label to detect, measure, or image cardiac tissue useful in the diagnosis of myocarditis. In certain embodiments, the peptides are conjugated to a particle coating for use in ultrasound imaging, MRI, or targeted therapy. In certain embodiments, peptides disclosed herein are conjugated to a drug or a particle containing a drug useful for targeted therapy.Type: ApplicationFiled: June 19, 2018Publication date: December 20, 2018Inventors: Michael Davis, Mario Martinez
-
Publication number: 20180362585Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.Type: ApplicationFiled: June 20, 2018Publication date: December 20, 2018Inventors: Daniel Paul Teufel, Catherine Stace, Edward Walker, John Tite
-
Publication number: 20180362586Abstract: In alternative embodiments, provided are compositions, including e.g., isolated, synthetic or recombinant peptides or polypeptides, for: expanding regulatory T cells (Treg) populations; or, for treating, ameliorating, preventing or reversing a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities and the same or similar types of acute or chronic vascular inflammatory abnormalities, and methods for making and using them.Type: ApplicationFiled: June 28, 2018Publication date: December 20, 2018Inventor: Alessandra FRANCO
-
Publication number: 20180362587Abstract: The invention provides compositions and methods for inhibiting protein-protein interactions with cap-binding protein 80 (CBP80). In one embodiment, the invention provides compositions comprising linear and macrocylic peptides. In one embodiment, the invention provides methods for treating cancer, heart disease, autoimmune disorders, obesity, diabetes, or chronic inflammation disorders associated with the PGC1 family of co-activators.Type: ApplicationFiled: December 8, 2016Publication date: December 20, 2018Inventors: Michael Gleghorn, Lynne Maquat, Rudi Fasan
-
Publication number: 20180362588Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.Type: ApplicationFiled: December 19, 2016Publication date: December 20, 2018Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI
-
Publication number: 20180362589Abstract: The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Applicant: MERIAL INC.Inventors: Loic Le Hir de Fallois, Greg Pacofsky, Alan Long, Charles Meng, Hyoung Ik Lee, Cyprian O. Ogbu
-
Publication number: 20180362590Abstract: Disclosed herein are novel polypeptides having nuclease activity. The Mmc3 polypeptides function as Class 2 Type V effectors, and catalyze double stranded breaks in nucleic acid strands. The polypeptides are useful, for example, for gene editing systems such as CRISPR, to make site specific alterations of target nucleic acid sequences.Type: ApplicationFiled: April 13, 2018Publication date: December 20, 2018Inventors: Russell David Monds, Simone Moraes Mantovani, Russell S. Komor, Matthew Carey LaFave, Krishna Kannan, Joseph W. LaMattina, Joseph S. Lucas, Eric R. Moellering
-
Publication number: 20180362591Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: ApplicationFiled: January 15, 2016Publication date: December 20, 2018Inventors: Adam Frederik Sander Pedersen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbæk, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Publication number: 20180362592Abstract: The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: ApplicationFiled: June 27, 2018Publication date: December 20, 2018Applicant: University of MassachusettsInventors: Guangping Gao, Terence Flotte, Jun Xie
-
Publication number: 20180362593Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: April 4, 2018Publication date: December 20, 2018Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Publication number: 20180362594Abstract: The present disclosure provides variant OmpG polypeptides, compositions comprising the OmpG variant polypeptides, and methods for using the variant OmpG polypeptides as nanopores for determining the sequence of single stranded nucleic acids. The variant OmpG nanopores reduce the ionic current noise versus the parental OmpG polypeptide from which they are derived and thereby enable sequencing of polynucleotides with single nucleotide resolution. The reduced ionic current noise also provides for the use of these OmpG nanopore variants in other single molecule sensing applications, e.g., protein sequencing.Type: ApplicationFiled: September 20, 2016Publication date: December 20, 2018Applicant: GENIA TECHNOLOGIES, INC.Inventors: Cynthia CECH, Tim CRAIG, Christos TZITZILONIS, Alexander YANG, Liv JENSEN, Charlotte YANG, Corissa HARRIS
-
Publication number: 20180362595Abstract: The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.Type: ApplicationFiled: August 27, 2018Publication date: December 20, 2018Inventors: Nanying Bian, Neil Soice, Shari Spector, Kara Levine
-
A GENETICALLY MODIFIED YEAST CELL AND IMPROVED PROCESS FOR PRODUCTION OF CLOT-SPECIFIC STREPTOKINASE
Publication number: 20180362596Abstract: Disclosed herein is an expression system for the production and secretion of biologically active clot-specific streptokinase (CSSK) protein in methylotrophic yeast. Yeast-expressed CSSK protein displays improved plasminogen activation and fibrin selectivity. Further disclosed are methylotrophic yeast transformed with at least one copy of functional cDNA sequence encoding CSSK adjunct with modified signal sequence which results in secretion of mature and correctly processed CSSK.Type: ApplicationFiled: October 26, 2016Publication date: December 20, 2018Applicant: Council of Scientific & Industrial ResearchInventors: Girish Sahni, Kishore Kumar Joshi -
Publication number: 20180362597Abstract: Provided herein are novel proteins and protein domains from newly discovered anaerobic fungal species. The anaerobic fungal species have unique enzymatic capabilities, including the ability to digest diverse lignocellulosic biomass feedstocks and to synthesize secondary metabolites. The scope of the invention encompasses novel engineered proteins comprising glycoside hydrolase enzymes, dockerin domains, carbohydrate binding domains, and polyketide synthase enzymes. The invention further encompasses artificial cellulosomes comprising novel proteins and domains of the invention. The scope of the invention further includes novel nucleic acid sequences coding for the engineered proteins of the invention, and methods of using such engineered organisms to degrade lignocellulosic biomass and to create polyketides.Type: ApplicationFiled: December 8, 2016Publication date: December 20, 2018Applicant: The Regents of the University of CaliforniaInventors: Michelle O'Malley, Kevin Solomon, Charles Haitjema
-
Publication number: 20180362598Abstract: A peptide comprised of either a binary or a tertiary peptide, the peptide contains at least 4 amino acids and up to a maximum of 16 amino acids, comprised of 2 or 3 different regions, wherein the binary peptides have 2 different regions and the tertiary peptides have 3 different regions; wherein, the peptide can be cleaved by both an animal gut protease and an insect or nematode gut protease.Type: ApplicationFiled: October 6, 2017Publication date: December 20, 2018Applicant: VESTARON CORPORATIONInventors: ALVAR R. CARLSON, ALEXANDRA M. HAASE, ROBERT M. KENNEDY
